Company intelligence / Profile preview

PDC Biotech

Ownership: Private
Development stage: Phase 1

Overview

PDC Biotech is developing PDC31, a peptide antagonist of the prostaglandin F2a (FP) receptor for the treatment of preterm labor and primary dysmenorrhea. The compound was licensed from Theratechnologies.

Therapeutic areas: Women's Health
Modalities: Peptides
Industry: Biotech

Drug pipeline

1 asset

PDC31

Partnerships

Theratechnologies (TSX: TH)

Beyond the preview

Go deeper on PDC Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDC Biotech.

Explore the full profile